hydroxytamoxifen

Subscribe to Selected New Research on hydroxytamoxifen

54 relevant articles (0 outcomes, 5 trials/studies) found for this Bio-Agent

Description: an estrogen antagonist

Bio-Agent Context: Research Results

Organic Chemicals: 42

Hydrocarbons: 362

Cyclic Hydrocarbons: 3

Aromatic Hydrocarbons: 121

Benzene Derivatives: 9

Benzylidene Compounds

Stilbenes: 43

Tamoxifen: 8020

hydroxytamoxifen: 54

Experts

1.	Vivacqua, Adele: 1 article (03/2006)
2.	Recchia, Anna Grazia: 1 article (03/2006)
3.	Andò, Sebastiano: 1 article (03/2006)
4.	Bonofiglio, Daniela: 1 article (03/2006)
5.	Maggiolini, Marcello: 1 article (03/2006)
6.	Picard, Didier: 1 article (03/2006)
7.	Musti, Anna Maria: 1 article (03/2006)
8.	Glienke, Wolfgang: 1 article (12/2004)
9.	Dolgova, Yuliya: 1 article (12/2004)
10.	Jonas, Dietger: 1 article (12/2004)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 03/01/2004 - "Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cells." 08/01/2000 - "Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling." 06/14/2009 - "A DFT study on the mechanism of a novel, regioselective, intramolecular N-pi rearrangement of cis and trans-eta1-N-CpRh-hydroxytamoxifen complexes to their eta6 derivatives; potential breast cancer pharmaceuticals, and fluorescent probes." 03/04/2009 - "We show here for ER-negative human breast cancer cells that the activation of GPR30 signalling by oestrogen or by hydroxytamoxifen (OHT), an ER antagonist but GPR30 agonist, induces a transcription factor network, which resembles that induced by serum in fibroblasts. " 08/01/2004 - "VEGF-D expression was enhanced by oestrogen in MCF-7 and T47D breast cancer cells, and was blocked by hydroxytamoxifen. " Order ALL the reference details at left...*
2.	Neoplasms (Cancer) 11/01/2006 - "We recently reported the dual (antihormonal and cytotoxic) functionality of ferrocifens, which are organometallic complexes derived from hydroxytamoxifen, the standard molecule in the treatment of hormone-dependent breast cancers. " 12/01/2002 - "In contrast, the oxidized forms of some cancer-preventive agents, such as polyphenolics (ellagic acid, 4-hydroxytamoxifen and curcumin) and selenocompounds, can inactivate PKC by oxidizing the vicinal thiols present within the catalytic domain. " 05/01/1989 - "The steroid hormone receptor content of 32 malignant ovarian tumors was compared with the in vitro effectiveness of 4 hydroxytamoxifen (OH-TAM) and medroxy-progesterone acetate (MPA) tested in the Human Tumor Colony Forming Assay (HTCFA). " 08/04/2003 - "The goal of our study was to potentiate the effects of the ((R,R)-trans-1,2-diaminocyclohexane)-platinum(II) fragment [(DACH)Pt], known for its cytotoxic properties, either with tamoxifen (Tam), the most widely used antiestrogen in the treatment of hormone-dependent breast cancers, or with its active metabolite hydroxytamoxifen (hydroxy-Tam). " 11/29/1994 - "To analyse further which of these targets are primarily involved in the antiproliferative activity of these drugs against human breast cancers, two cell clones, namely the RTx6 and LY-2 variants, selected from MCF-7 cells for their resistance to high doses of tamoxifen (TAM) and the Keoxifen (KEO) analog LY 117018, respectively, were studied for their sensitivity to hydroxytamoxifen (OH-TAM) and KEO as well as the strong calmodulin antagonist calmidazolium. " Order ALL the reference details at left...
3.	Hepatocellular Carcinoma (Hepatoma) 01/11/2008 - "Similarly, SeP mRNA was upregulated in response to activation of FoxO1a in rat hepatoma cells stably transfected with a hydroxytamoxifen-regulatable form of FoxO1a. " 09/15/2004 - "We generated two H4IIEC3 rat hepatoma cell lines stably expressing either a hydroxytamoxifen-regulatable form of PKB (myristoylated PKB estrogen receptor chimera; MER-PKB) or FKHR (FKHR estrogen receptor chimera; FKHR-ER) by retroviral infection and determined the regulation of the G6Pase transcript by Northern blotting and enzyme assays. " Order ALL the reference details at left...
4.	Neurodegenerative Diseases (Neurodegenerative Disease) 07/01/2004 - "Since numerous neurodegenerative diseases are intimately related with mitochondrial dysfunction resulting from lipid peroxidation and induction of mitochondrial permeability transition, among other factors, future therapeutical strategies could be designed taking in account this neuroprotective role of hydroxytamoxifen, which is pharmacologically much more potent and less toxic than its promoter tamoxifen." Order ALL the reference details at left...
5.	Endometrial Neoplasms (Endometrial Cancer) 03/01/2006 - "The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Estrogen Receptor Modulators (Antiestrogen)
3.	Estrogens (Estrogen)
4.	Hormones
5.	Fluorescent Dyes (Fluorescent Probes)
6.	Carbon Monoxide
7.	1,2-cyclohexanediamine (dach)
8.	N-desmethyltamoxifen
9.	Estradiol (Estrace)
10.	hydroxide ion

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3868 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>